This article needs additional citations for verification. (July 2020) (Learn how and when to remove this template message)
|Marc Coucke (Founder)|
|Products||Prescription-free medicines and healthcare products|
|Revenue||€1.27 billion (2014)|
|€200 million (2014)|
|€69.5 million (2010)|
|Total assets||€1.443 billion (end 2010)|
|Total equity||€718.3 million (end 2010)|
Number of employees
|2,130 (end 2010)|
|Parent||Perrigo Company plc|
Omega Pharma was a Belgian-based pharmaceutical company which was acquired in 2014 by Perrigo Company plc, an Irish/U.S.-based global pharmaceutical public company. The company was founded in 1987 and was based in the Industrial area 'de Prijkels' in Nazareth.
The company was founded in 1987 by Marc Coucke and Yvan Vindevogel, both former pharmacy students at the Ghent University. They each had a 50% share in the company. Their first product was a shampoo in 5 liter bottles which they sold to pharmacists who then added a customised scent and colour to sell the product as a homemade brand. In 1989 they started selling Uvesol tanning lotions. In 1994 Yvan Vindevogel sold his shares to Marc Coucke.
in 1998 was the company's initial public offering (IPO). Omega Pharmaa was initially listed as a Naamloze vennootschap on the Euronext Brussels and used to be part of the BEL20 index until late 2011 when Coucke and private equity firm Couckinvest en Waterland took the company private once again. Omega Pharma was officially acquired by Perrigo with effect from 31 March 2015. The company is now part of the Branded Consumer Healthcare division within Perrigo.
At the annual shareholders meeting of Omega Pharma held on 6 June 2006, it was announced that the company's professional health division would operate under the name of Arseus. Simultaneously, the management team of Arseus was presented. The legal structure of the entities in this division has been largely prepared in the meantime, so that the project to make Arseus an autonomous company is on schedule. Arseus became effectively an independent entity via an IPO on 5 October 2007 and has been listed on NYSE Euronext Brussels and NYSE Euronext Amsterdam since then.
|This article about a medical, pharmaceutical or biotechnological corporation or company is a stub. You can help Wikipedia by expanding it.|